1900 Wealth Management LLC Grows Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

1900 Wealth Management LLC lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,294 shares of the medical research company’s stock after buying an additional 40 shares during the quarter. 1900 Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $687,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of TMO. Raleigh Capital Management Inc. lifted its stake in shares of Thermo Fisher Scientific by 49.1% in the third quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock worth $41,000 after buying an additional 27 shares in the last quarter. Cedar Mountain Advisors LLC lifted its position in Thermo Fisher Scientific by 107.0% during the fourth quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 46 shares during the period. Operose Advisors LLC lifted its position in Thermo Fisher Scientific by 250.0% during the third quarter. Operose Advisors LLC now owns 105 shares of the medical research company’s stock valued at $53,000 after purchasing an additional 75 shares during the period. Financial Connections Group Inc. bought a new position in Thermo Fisher Scientific during the fourth quarter valued at approximately $53,000. Finally, Valley National Advisers Inc. lifted its position in Thermo Fisher Scientific by 40.5% during the third quarter. Valley National Advisers Inc. now owns 111 shares of the medical research company’s stock valued at $56,000 after purchasing an additional 32 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling

In other Thermo Fisher Scientific news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the sale, the director now owns 1,207 shares of the company’s stock, valued at $660,192.79. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, CEO Marc N. Casper sold 5,547 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $550.62, for a total transaction of $3,054,289.14. Following the completion of the transaction, the chief executive officer now owns 43,608 shares of the company’s stock, valued at approximately $24,011,436.96. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Debora L. Spar sold 164 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the transaction, the director now directly owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The disclosure for this sale can be found here. Insiders sold a total of 50,277 shares of company stock valued at $28,513,384 over the last three months. 0.32% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Trading Up 4.1 %

Shares of TMO traded up $22.42 during mid-day trading on Tuesday, reaching $570.80. The stock had a trading volume of 905,502 shares, compared to its average volume of 1,540,551. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $603.82. The business’s fifty day moving average is $571.30 and its 200 day moving average is $528.18. The firm has a market cap of $217.88 billion, a price-to-earnings ratio of 35.49, a P/E/G ratio of 2.30 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The business had revenue of $10.89 billion for the quarter, compared to analysts’ expectations of $10.73 billion. During the same quarter in the prior year, the company earned $5.40 earnings per share. The business’s quarterly revenue was down 4.9% on a year-over-year basis. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.51 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were given a dividend of $0.39 per share. The ex-dividend date of this dividend was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.10%.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Evercore ISI upped their target price on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. The Goldman Sachs Group upped their target price on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Raymond James upped their target price on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. Barclays cut shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and upped their target price for the company from $475.00 to $555.00 in a report on Wednesday, January 24th. Finally, HSBC upped their target price on shares of Thermo Fisher Scientific from $630.00 to $660.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Five investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $604.69.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.